BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 31894841)

  • 1. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
    Huang Q; Xing S; Peng A; Yu Z
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4.
    Hu B; Zhang H; Wang Z; Zhang F; Wei H; Li L
    Cancer Biol Ther; 2017 Dec; 18(12):974-983. PubMed ID: 29020498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA NORAD/miR-202-5p regulates the drug resistance of A549/DDP to cisplatin by targeting P-gp.
    Shen JG; Xu SN; Yin LG
    Gen Physiol Biophys; 2020 Sep; 39(5):481-489. PubMed ID: 33084601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway.
    Xu L; Xu Y; Yang M; Li J; Xu F; Chen BL
    BMC Pulm Med; 2020 Oct; 20(1):266. PubMed ID: 33059643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of SOX4 on DDP Resistance in Non-small Cell Lung Cancer Cell of A549].
    Li W; Liu X; Zhang G; Zhang L
    Zhongguo Fei Ai Za Zhi; 2017 May; 20(5):298-302. PubMed ID: 28532536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
    Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
    Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circular RNA circ-RNF121 contributes to cisplatin (DDP) resistance of non-small-cell lung cancer cells by regulating the miR-646/SOX4 axis.
    Liu Y; Zhai R; Hu S; Liu J
    Anticancer Drugs; 2022 Jan; 33(1):e186-e197. PubMed ID: 34387608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
    Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
    Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
    Wang L; Shang X; Feng Q
    Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impacts of LncRNA NORAD on the Proliferation, Apoptosis, and Chemosensitivity of Non-small Cell Lung Cancer Cells by Regulating ZNF217 through MiR-199a-3p].
    Gao Y; Luo X; Liao P; Luo Y
    Zhongguo Fei Ai Za Zhi; 2023 Jul; 26(7):479-486. PubMed ID: 37653011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
    Liu B; Wang R; Liu H
    Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-129-2 upregulation induces apoptosis and promotes NSCLC chemosensitivity by targeting SOX4.
    Zhou W; Cai C; Lu J; Fan Q
    Thorac Cancer; 2022 Apr; 13(7):956-964. PubMed ID: 35146917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA NORAD targets miR-410-3p to regulate drug resistance sensitivity of osteosarcoma.
    Xie X; Liu W; Duan Z; Li X; Zhang L; Yang G
    Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):143-148. PubMed ID: 32538761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
    Shen Q; Xu Z; Xu S
    Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA NORAD promotes the occurrence and development of non-small cell lung cancer by adsorbing MiR-656-3p.
    Chen T; Qin S; Gu Y; Pan H; Bian D
    Mol Genet Genomic Med; 2019 Aug; 7(8):e757. PubMed ID: 31207175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ELF1 suppresses autophagy to reduce cisplatin resistance via the miR-152-3p/NCAM1/ERK axis in lung cancer cells.
    Zhao L; Wu X; Zhang Z; Fang L; Yang B; Li Y
    Cancer Sci; 2023 Jun; 114(6):2650-2663. PubMed ID: 36846943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
    Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
    Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM; Ge F; Chen XJ; Tang C; Ma J
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.